Sugi Predict

Sugi Predict / Compounds / SCHEMBL3077982

SCHEMBL3077982

SCHEMBL3077982

CCOC(=O)c1cnn2ccc(N)cc12

nearest known ligand 0.52

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 9/20 0.49
▸ HPGD P15428 4/20 0.49
▸ RAB9A P51151 4/20 0.49
▸ KMT2A Q03164 3/20 0.48
▸ TSHR P16473 2/20 0.48
▸ SMN1; SMN2 Q16637 2/20 0.48
▸ MEN1 O00255 2/20 0.48
▸ HTT P42858 1/20 0.47
▸ NPC1 O15118 3/20 0.47
▸ LMNA P02545 1/20 0.47
▸ KDM4E B2RXH2 5/20 0.47
▸ TP53 P04637 1/20 0.45
▸ HSD17B10 Q99714 2/20 0.44
▸ MAPT P10636 1/20 0.44
▸ HIF1A Q16665 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL26603916 0.99 ALDH1A1 (0.48) ALDH1A1HPGDRAB9AKMT2ATSHR
SCHEMBL3073456 0.86 ALDH1A1 (0.52) ALDH1A1HPGDRAB9AKMT2ATSHR
SCHEMBL13139917 0.85 CA12 (0.50) ALDH1A1HPGDRAB9AKMT2ATSHR
SCHEMBL16563455 0.85 ALDH1A1 (0.49) ALDH1A1HPGDRAB9AKMT2ATSHR
SCHEMBL24369481 0.84 HTT (0.53) ALDH1A1HPGDRAB9AKMT2ATSHR
SCHEMBL3074755 0.84 SMN1; SMN2 (0.46) ALDH1A1HPGDRAB9AKMT2ATSHR
SCHEMBL30935665 0.84 ALDH1A1 (0.47) ALDH1A1HPGDRAB9AKMT2ATSHR
SCHEMBL3078049 0.84 SMN1; SMN2 (0.46) ALDH1A1HPGDRAB9AKMT2ATSHR
SCHEMBL22228625 0.83 SMN1; SMN2 (0.45) ALDH1A1HPGDRAB9AKMT2ATSHR
SCHEMBL3084426 0.83 EPHB3 (0.54) ALDH1A1HPGDRAB9ASMN1; SMN2KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4262788-B1 UREA OREXIN RECEPTOR AGONISTS MERCK SHARP & DOHME LLC (US) 2026-01-21 — — EP disclosed
WO-2025149623-A1 WNK1 INHIBITORS DANIA THERAPEUTICS APS (DK) 2025-07-17 — — WO disclosed
US-12331046-B2 CTPS1 inhibitors and uses thereof NIMBUS CLOTHO, INC. (US) 2025-06-17 — — US disclosed
US-20250066318-A1 HETEROCYCLIC COMPOUNDS AS DYRK1A INHIBITORS PROTHENA BIOSCIENCES INC 2025-02-27 — — US disclosed
US-20250051363-A1 Substituted Pyrazolopyridines NEURO3 THERAPEUTICS INC (US) 2025-02-13 — — US disclosed
WO-2025029897-A1 SUBSTITUTED PYRAZOLOPYRIDINES NEURO3 THERAPEUTICS, INC. (US) 2025-02-06 — — WO disclosed
CN-118843626-A Heterocyclic compounds as DYRK1A inhibitors 普罗塞纳生物科学有限公司 2024-10-25 — — CN disclosed
EP-4444421-A2 HETEROCYCLIC COMPOUNDS AS DYRK1A INHIBITORS Prothena Biosciences Limited (IE) 2024-10-16 — — EP disclosed
US-20240101555-A1 UREA OREXIN RECEPTOR AGONISTS MERCK SHARP & DOHME LLC (US) 2024-03-28 — — US disclosed
WO-2023205475-A1 CTPS1 INHIBITORS AND USES THEREOF NIMBUS CLOTHO, INC. (US) 2023-10-26 — — WO disclosed
EP-2678338-A1 COMPOUNDS AND COMPOSITIONS AS TRK INHIBITORS IRM LLC (BM) 2014-01-01 — — EP disclosed
US-20130331397-A1 COMPOUNDS AND COMPOSITIONS AS TRK INHIBITORS IRM LLC (BM) 2013-12-12 — — US disclosed
WO-2012116217-A1 COMPOUNDS AND COMPOSITIONS AS TRK INHIBITORS IRM LLC (BM) 2012-08-30 — — WO disclosed
WO-2012116217-A1 COMPOUNDS AND COMPOSITIONS AS TRK INHIBITORS IRM LLC (BM) 2012-08-30 — — WO disclosed
US-20100226881-A1 PYRAZOLO[1,5-a]PYRIDINES AND THEIR USE IN CANCER THERAPY AUCKLAND UNISERVICES LIMITED (NZ) 2010-09-09 — — US disclosed
US-20100226881-A1 PYRAZOLO[1,5-a]PYRIDINES AND THEIR USE IN CANCER THERAPY AUCKLAND UNISERVICES LIMITED (NZ) 2010-09-09 — — US disclosed
US-20100226881-A1 PYRAZOLO[1,5-a]PYRIDINES AND THEIR USE IN CANCER THERAPY AUCKLAND UNISERVICES LIMITED (NZ) 2010-09-09 — — US disclosed
EP-2176260-A1 PYRAZOLO[1,5-A]PYRIDINES AND THEIR USE IN CANCER THERAPY AUCKLAND UNISERVICES LIMITED (NZ) 2010-04-21 — — EP disclosed
WO-2009008748-A1 PYRAZOLO[1,5-A]PYRIDINES AND THEIR USE IN CANCER THERAPY AUCKLAND UNISERVICES LIMITED (NZ) 2009-01-15 — — WO disclosed
WO-2009008748-A1 PYRAZOLO[1,5-A]PYRIDINES AND THEIR USE IN CANCER THERAPY AUCKLAND UNISERVICES LIMITED (NZ) 2009-01-15 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250066318-A1 HETEROCYCLIC COMPOUNDS AS DYRK1A INHIBITORS DYRK1A, DYRK2, DYRK1B ALDH1A1 3352/4885HPGD 3062/4885RAB9A 731/4885
US-20250051363-A1 Substituted Pyrazolopyridines QDPR, DPYD, P2RX4 ALDH1A1 729/4885HPGD 1280/4885RAB9A 1876/4885
US-20130331397-A1 COMPOUNDS AND COMPOSITIONS AS TRK INHIBITORS CNKSR1, BMP2K, RAF1 ALDH1A1 4150/4885HPGD 4133/4885RAB9A 2369/4885
US-20100226881-A1 PYRAZOLO[1,5-a]PYRIDINES AND THEIR USE IN CANCER THERAPY TP53, PNPO, DPYD ALDH1A1 588/4885HPGD 281/4885RAB9A 1073/4885
US-12331046-B2 CTPS1 inhibitors and uses thereof CTPS1, CTPS2, ECHS1 ALDH1A1 1472/4885HPGD 1139/4885RAB9A 3544/4885
US-20240101555-A1 UREA OREXIN RECEPTOR AGONISTS HCRTR1, HCRTR2, UTS2R ALDH1A1 2124/4885HPGD 1166/4885RAB9A 2258/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.